Table 3 Risk factors for prolonged fever following macrolide treatment
Parameters | Fever duration following macrolide treatment | Univariate model | Multivariate model | |||
|---|---|---|---|---|---|---|
<7 days (N = 79) | ≥7 days (N = 37) | P | aORa | P | 95% CI | |
Male gender | 40 (50.6) | 19 (51.4) | 0.942 | Â | Â | Â |
Age in years, mean ± SD | 5.8 ± 3.2 | 6.3 ± 3.9 | 0.499 |  |  |  |
Macrolide resistance | 51 (64.6) | 31 (83.8) | 0.034 | 2.687 | 0.072 | 0.917–7.878 |
Extrapulmonary signs | 9 (11.4) | 12 (32.4) | 0.006 | 3.037 | 0.039 | 1.057–8.726 |
Radiology findings | ||||||
 Lobar consolidation | 21 (26.6) | 23 (62.2) | 0.000 | 3.610 | 0.004 | 1.519–8.580 |
 Patchy consolidation | 27 (34.2) | 10 (27.0) | 0.441 |  |  |  |
 Nodular opacities | 15 (19.0) | 4 (10.8) | 0.420 |  |  |  |
 Parahilar infiltration | 16 (20.3) | 0 (0) | 0.003 |  |  |  |
 Parapneumonic effusion | 5 (6.3) | 17 (45.9) | 0.000 | 9.705 | 0.000 | 3.031–31.075 |